




RealRate

PHARMACEUTICAL 2019

Alaunos Therapeutics Inc.
Rank 226 of 371

ALAUNOS[™]
THERAPEUTICS



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2019

Alaunos Therapeutics Inc.
Rank 226 of 371



The relative strengths and weaknesses of Alaunos Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alaunos Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 210% points. The greatest weakness of Alaunos Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 158% points.

The company's Economic Capital Ratio, given in the ranking table, is -233%, being 99% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	84,285
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,483
Liabilities, Non-Current	0
Other Assets	9,669
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	4.0
Other Net Income	789
Property and Equipment	1,097
Research and Development	34,134
Revenues	146
Selling, General and Administrative Expense	19,918

Output Variable	Value in 1000 USD
Assets	95,051
Liabilities	9,487
Expenses	54,052
Stockholders Equity	85,564
Net Income	-53,117
Comprehensive Net Income	-53,117
Economic Capital Ratio	-233%

